Trial Profile
A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 09 Mar 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 20 Jan 2024 Results of pooled analysis from NCT02870920 and NCT02879318; investigating the incidence of CHIP in ctDNA from patients with gastrointestinal (GI) cancers and explored its association with outcomes and adverse events , presented at the 2024 Gastrointestinal Cancers Symposium
- 03 Aug 2023 Planned End Date changed from 30 Jun 2023 to 31 Dec 2023.